The E.W. Scripps Company

Quotes on U.S. broadcaster the E.W. Scripps Company soared more than 40% yesterday, March 12. The rally was driven by two positive news items: The company <a href="https://scripps.com/press-releases/scripps-announces-a-series-of-transactions-to-refinance-its-revolver-and-2026-2028-term-loans/">secured</a> refinancing for its term loans and reported strong financial results for the fourth quarter.

U.S. broadcaster Scripps surges on refinancing agreement and fourth-quarter earnings


Stitch Fix, Inc.

Quotes on Stitch Fix, a small-cap company that uses AI to assist customers in selecting clothes, <a href="https://www.marketwatch.com/investing/stock/sfix?mod=mw_quote_tab">soared</a> more than 20% in premarket trading today, March 12, after it <a href="https://investors.stitchfix.com/news-releases/news-release-details/stitch-fix-announces-second-quarter-fiscal-year-2025-financial">reported</a> stronger-than-expected earnings for the second quarter and upgraded its 2025 full-year guidance.

AI stylist Stitch Fix advances on upgraded 2025 guidance


Shares of 2Seventy Bio, a small-cap maker of targeted cancer therapies, <a href="https://finance.yahoo.com/quote/TSVT/">skyrocketed</a> almost 80% yesterday, March 11, after the company <a href="https://ir.2seventybio.com/news-releases/news-release-details/2seventy-bio-enters-definitive-agreement-be-acquired-bristol">announced</a> that pharmaceutical giant Bristol Myers Squibb would acquire it at an 88% premium.

2Seventy Bio, trying to ‘outmaneuver cancer,’ soars after acquisition by BMS

Shares of Redfin Corporation, which owns an online real estate marketplace with over a million listings for sale and rent, have soared 66% this week following <a href="https://investors.redfin.com/news-events/press-releases/detail/1288/rocket-companies-to-acquire-redfin-accelerating-purchase">news</a> of its acquisition by fintech platform Rocket Companies. The combined company is expected to achieve more than $200 million in run-rate synergies by 2027 thanks to cross-selling and eliminating duplicative operations, according to the acquisition announcement.

Online real estate marketplace Redfin surges on news of acquisition by Rocket


Comtech Telecommunications Corp.

Quotes on Comtech Telecommunications, a micro-cap provider of satellite and space communications technologies, <a href="https://finance.yahoo.com/quote/CMTL/">soared</a> almost 12% yesterday, March 10, despite a sharp drop in the Nasdaq Composite index. This came after the company <a href="https://comtech.com/press-releases/2025/03/10/comtech-secures-26-million-in-sole-source-contracts-from-l3harris-to-advance-next-generation-protected-satcom-programs/">announced</a> contracts worth $26 million with defense contractor L3Harris Technologies to advance protected satellite communications programs.

Micro-cap communications technology provider Comtech gains despite Nasdaq selloff


LifeMD, Inc.

Shares of LifeMD, a company that provides online healthcare services and offers a web platform for streamlining workplace tasks, <a href="https://www.marketwatch.com/investing/stock/lfmd">surged</a> nearly 20% early in the day today, March 11. The <a href="https://ir.lifemd.com/press-release-details.php?newsId=3040216">trigger</a> was the company’s “great fourth quarter,” in particular, that of the weight management program. From April, LifeMD will start working with Medicare, which is expected to be a “significant growth driver” for its business.

Weight-loss trend boosts LifeMD top and bottom lines


Quotes on Checkpoint Therapeutics, a small-cap company specializing in cancer treatments, jumped more than 60% despite a massive selloff in the U.S. stock market yesterday, March 10. The surge came after the company <a href="https://ir.checkpointtx.com/news-events/press-releases/detail/128/sun-pharma-to-acquire-checkpoint-therapeutics">announced</a> that India's pharmaceutical giant Sun Pharma would acquire it at a premium. Checkpoint’s flagship product is Cosibelimab, an FDA-approved skin cancer treatment.

Cancer drugmaker Checkpoint Therapeutics soars 60% amid market crash

IDT Corporation

Shares of fintech small cap IDT Corporation <a href="https://www.marketwatch.com/investing/stock/idt/analystestimates?mod=mw_quote_tab">surged</a> more than 10% on Friday, March 7. The company <a href="https://www.idt.net/idt-corporation-reports-record-second-quarter-2025-results-2/">reported</a> double-digit growth in fiscal-2025 second-quarter gross profit and announced a 20% boost to its regular quarterly dividend and an acceleration of its share buyback program.

Fintech small cap IDT Corp. soars on earnings, higher dividend 


Acurx Pharmaceuticals, Inc.

Quotes on Acurx Pharmaceuticals, a micro-cap company developing new types of antibiotics for difficult-to-treat bacterial infections, <a href="https://www.marketwatch.com/investing/stock/acxp">shed</a> 30% on Friday, March 7, hitting an all-time low. This followed the company’s <a href="https://ir.acurxpharma.com/press-releases/detail/103/acurx-pharmaceuticals-inc-announces-1-1-million">announcement</a> of a direct offering at a significant discount to the market share price. Note that this is Acurx’s <a href="https://www.acurxpharma.com/news-media/press-releases/detail/98/acurx-pharmaceuticals-inc-announces-closing-of-2-5">second</a> direct offering in the past two months.

Novel antibiotic maker Acurx loses third of market value after new offering announced

Shares of Kestra Medical Technologies, a small-cap maker of wearable defibrillators, <a href="https://finance.yahoo.com/quote/KMTS/?guccounter=1&amp;guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&amp;guce_referrer_sig=AQAAANJzO7qhtq4ftfonGEodVUta3W7CcmJ8wkHgYAForTOSW-XBS4xlKF7KLyQk0L35CoYcX_jqygts2GD4qGMiFBIdNwS4SdNJF98C33sKbOp9lSNggPnmigup5BLKbWDPzB_A28f6kwvxv2u7wovLH2Nc3V4Qa7V3KMWqsBlp24tN">soared</a> more than 28% yesterday, March 6, its first day of trading as a public stock. Amid high demand for the company’s shares in the IPO, Kestra ended up <a href="https://investors.kestramedical.com/news-releases/news-release-details/kestra-medical-technologies-ltd-announces-pricing-upsized">offering</a> more shares and at a higher price than <a href="https://investors.kestramedical.com/news-releases/news-release-details/kestra-medical-technologies-ltd-announces-launch-initial-public">initially planned</a>.

Wearable defibrillator maker Kestra surges almost 30% on debut trading day

ProMIS Neurosciences, Inc.

ProMIS Neurosciences, with a market <a href="https://www.marketwatch.com/investing/stock/pmn?mod=mw_quote_tab">capitalization</a> of about $24 million on the Nasdaq, started out as a developer of mad cow disease tests but has since shifted focus to treating Alzheimer’s and other neurodegenerative diseases. Bloomberg has <a href="https://www.bloomberg.com/news/articles/2025-01-10/alzheimer-s-drugs-from-lilly-novo-and-roche-in-focus-for-investors?sref=Y0jVLcFo&amp;utm_source=in_materials#:~:text=Investors%20seeking%20the%20next%20obesity%2Dlike%20market%20opportunity%20will%20be%20closely%20watching%20developments%20related%20to%20treatments%20for%20Alzheimer%E2%80%99s%20disease%20in%202025.">said</a> this space offers some of the most promising investment opportunities.

ProMIS, taking aim at Alzheimer’s, could have 900% upside


Shares of Chimerix, a small-cap cancer drugmaker, <a href="https://finance.yahoo.com/quote/CMRX/">surged</a> more than 70% today, March 6, after the company <a href="https://ir.chimerix.com/news-releases/news-release-details/jazz-pharmaceuticals-acquire-chimerix-further-diversifying">announced</a> that it would be acquired at a premium by a larger peer, Jazz Pharmaceuticals, which seeks to strengthen its position in the oncology space. Chimerix's lead drug candidate treats brain tumors with a specific mutation. Noble Capital Markets <a href="https://www.channelchek.com/news-channel/jazz-pharmaceuticals-acquires-chimerix-in-935-million-deal-to-expand-oncology-pipeline">points out</a> that if approved, it could become a breakthrough treatment.

Small caps